After strutting its stuff against blockbusters in three head-to-head psoriasis trials, UCB’s Bimzelx has conquered another ...

New data show bimekizumab is the first approved biologic to achieve superior outcomes in psoriatic arthritis vs an IL-23 ...

Please provide your email address to receive an email when new articles are posted on . Izokibep achieved ACR50 response at week 16 in a phase 2b/3 PsA trial and showed continued benefit in a ...

AbbVie (ABBV) stock is in focus as UCB (UCBJY) says its Bimzelx beat Skyrizi in a head-to-head psoriatic arthritis trial.

ATLANTA, March 11, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive topline data from the BE BOLD trial assessing BIMZELX ® (bimekizumab) versus SKYRIZI ® ...

LOS ANGELES, March 11, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines ...

In these phase 3 findings presented at ACR 2023, the safety and efficacy of this drug was proven in American College of Rheumatology-20 (ACR20), ACR50, and Disease Activity Score in 28 joints with ...

Findings showed 31.7% of patients receiving ixekizumab and tirzepatide achieved both ACR50 and at least 10% weight loss vs 0.8% on ixekizumab monotherapy. Topline data were announced from a phase 3b ...

MILAN -- A novel oral agent that blocks two different kinase enzymes was possibly more effective against rheumatoid arthritis (RA) than the currently approved drug tofacitinib (Xeljanz) in a ...

UCB has announced positive topline results from its BE BOLD trial, the first head‑to‑head study in active psoriatic arthritis ...

A decision-analytic model could save more than $7 million in overall ineffective health care costs per 1000 patients by predicting which patients with rheumatoid arthritis (RA) will have an inadequate ...